Susquehanna Fundamental Investments’s BridgeBio Pharma BBIO Stock Holding History

Susquehanna Fundamental Investments’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$289K	Buy	+3,874	New	+$271K	0.01%	655
2025 Q4	–	Sell	-86,394	Closed	-$4.49M	–	570
2025 Q3	$4.49M	Sell	86,394 -92,512	-52%	-$4.51M	0.18%	144
2025 Q2	$7.73M	Sell	178,906 -74,889	-30%	-$2.72M	0.21%	139
2025 Q1	$8.77M	Buy	253,795 +15,800	+7%	+$533K	0.12%	210
2024 Q4	$6.53M	Buy	+237,995	New	+$6.15M	0.09%	273
2024 Q2	$4.25M	Buy	+167,839	New	+$4.59M	0.1%	259
2024 Q1	–	Sell	-42,029	Closed	-$1.7M	–	668
2023 Q4	$1.7M	Sell	42,029 -71,081	-63%	-$2.13M	1.72%	15
2023 Q3	$2.98M	Hold	113,110	–	–	0.19%	119
2023 Q2	$1.95M	Hold	113,110	–	–	0.07%	253
2023 Q1	$1.88M	Hold	113,110	–	–	0.04%	388
2022 Q4	$862K	Buy	113,110 +97,510	+625%	+$934K	0.01%	693
2022 Q3	$155K	Buy	+15,600	New	+$162K	﹤0.01%	1294
2022 Q1	$158K	Sell	15,600 -19,900	-56%	-$204K	﹤0.01%	1403
2021 Q4	$592K	Buy	+35,500	New	+$1.5M	0.02%	849

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Susquehanna Fundamental Investments's BBIO Position: Q2 2026 in Review

Susquehanna Fundamental Investments opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 3,874 shares worth $289K. The stake represents 0.01% of the portfolio and ranks #655 among its holdings. This is a return to the name: Susquehanna Fundamental Investments previously reported a position in BBIO as recently as Q3 2025.

Susquehanna Fundamental Investments first reported a position in BBIO in Q4 2021 and has held it in 14 quarters since. The position peaked at $8.77M in Q1 2025. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Susquehanna Fundamental Investments held 3,874 shares of BridgeBio Pharma worth $289K as of Q2 2026.
BridgeBio Pharma was a new Susquehanna Fundamental Investments position in Q2 2026.
BridgeBio Pharma made up 0.01% of Susquehanna Fundamental Investments's portfolio in Q2 2026, its #655 holding.
Susquehanna Fundamental Investments first reported a position in BridgeBio Pharma in Q4 2021 and has held it in 14 quarters since.
Susquehanna Fundamental Investments's BridgeBio Pharma position peaked at $8.77M in Q1 2025.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2026, filed 14 Aug 2026.